PCA3, PCAT-1, MALAT1, miR-205, miR-34a, and even many other ncRNAs have been reported to be involved in the onset and progression of prostate cancer, and they can be used as potential biomarkers and therapeutic targets for prostate cancer [4,5]. This evidence concerns the gene PCAT1 and prostate carcinoma.